Furosemide Injection Shortage: Current Status
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Furosemide Injection, a cardiovascular medication, is in a current shortage with some manufacturers facing availability issues due to manufacturing delays.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Furosemide.
Furosemide Injection Shortage
What's in Shortage
Furosemide Injection is the generic name, with brand name FUROSEMIDE. It is available as an Injection dosage form and is currently in shortage status. The shortage was first posted on 04/07/2020 and last updated on 04/01/2026. It falls under the therapeutic category of Cardiovascular.
Which Manufacturers Are Affected
- Baxter Healthcare: Available for presentations such as Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25, 36000-283-25, 36000-284-25). Contact info: 888-229-0001.
- Fresenius Kabi USA, LLC: Available for presentations such as Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04, 63323-280-10, 63323-280-02). Related info: Check wholesalers for inventory. Contact info: 888-386-1300.
- Avet Pharmaceuticals, Inc.: Available for some presentations like Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41, 23155-473-42, 83634-302-10, 83634-302-04), but unavailable for Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44) due to manufacturing delay with estimated availability on 6/15/2026. Related info: Distributed by Avenacy; Contact information: 877-283-6229. Contact info: 855-228-9470.
- Hospira, Inc., a Pfizer Company: Unavailable for some presentations such as Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26) with next delivery in December 2027, Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25) with next delivery in December 2027, and Furosemide, Injection, 100 mg/10 mL (10 mg/1 mL) (NDC 0409-6102-27) with next delivery in December 2028 due to manufacturing delays. Available for Furosemide, Injection, 100 mg/10 mL (10 mg/1 mL) (NDC 0409-6102-10), 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04), and 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02). Contact info: 844-646-4398.
Why There's a Shortage
For some manufacturers, the shortage is due to manufacturing delays, as indicated in the source data.
What Patients Should Do
Patients experiencing issues with obtaining Furosemide Injection should talk to their pharmacist or healthcare provider to check availability and discuss options. They can also contact the relevant manufacturer for more information. Patients should consult their healthcare provider for any medical advice and not make changes to their treatment without professional guidance.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (2,397 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.